Immatics (IMTX) Total Current Liabilities (2019 - 2025)
Immatics' (IMTX) quarterly Total Current Liabilities came in at $50.1 million in Q4 2025, down 31.08% year-on-year from $72.7 million in Q4 2024, and down 31.21% quarter-over-quarter from $72.8 million in Q3 2025.
Immatics (IMTX) Total Current Liabilities (2019 - 2025) Analysis & Trends
Immatics has disclosed Total Current Liabilities across 7 years of filings, most recently posting $50.1 million for Q4 2025.
- Total Current Liabilities for Q4 2025 came in at $50.1 million, down 31.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $50.1 million (down 31.08% YoY), and the FY2025 annual result was $48.6 million, down 33.11% from the prior year.
- Total Current Liabilities came in at $50.1 million for Q4 2025 at Immatics, down from $72.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $168.4 million in Q4 2023 to a low of $50.1 million in Q4 2025.
- The 5-year median for Total Current Liabilities is $111.0 million (2021), against an average of $111.9 million.
- Across the five-year window, Total Current Liabilities soared 55.09% in 2023 and tumbled 63.78% in 2025, its largest moves.
- Immatics' Total Current Liabilities stood at $108.8 million in 2021, then dropped by 0.22% to $108.6 million in 2022, then jumped by 55.09% to $168.4 million in 2023, then plunged by 56.87% to $72.7 million in 2024, then tumbled by 31.08% to $50.1 million in 2025.
- The last three Total Current Liabilities figures came in at $50.1 million (Q4 2025), $72.8 million (Q3 2025), and $64.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | 50.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 50.07 Mn |
| Sep 30, 2025 | 72.78 Mn |
| Jun 30, 2025 | 64.80 Mn |
| Mar 31, 2025 | 58.66 Mn |
| Dec 31, 2024 | 72.65 Mn |
| Sep 30, 2024 | 141.57 Mn |
| Jun 30, 2024 | 161.04 Mn |
| Mar 31, 2024 | 161.98 Mn |
| Dec 31, 2023 | 168.44 Mn |
| Sep 30, 2023 | 131.88 Mn |
| Jun 30, 2023 | 135.36 Mn |
| Mar 31, 2023 | 107.96 Mn |
| Dec 31, 2022 | 108.61 Mn |
| Sep 30, 2022 | 125.15 Mn |
| Jun 30, 2022 | 121.64 Mn |
| Mar 31, 2022 | 103.09 Mn |
| Dec 31, 2021 | 108.85 Mn |
| Sep 30, 2021 | 126.33 Mn |
| Jun 30, 2021 | 113.12 Mn |
| Mar 31, 2021 | 103.84 Mn |